Table 1.
Pathological and immunohistochemical parameters in breast cancer and breast cancer cluster methylated groups
| All Samples | Cluster Groups | x2 | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||
| Parameter/Event | Event (%) | n | Highly methylated | Sparsely methylated | Adjusted p | ||||
|
|
|||||||||
| Event (%) | n | Event (%) | n | ||||||
| Pathological characteristics | T | 1 | 56 (58) | 97 | 10 (62) | 16 | 46 (57) | 81 | ns |
| 2 | 41 (42) | 97 | 6 (38) | 16 | 35 (43) | 81 | |||
| N | 0 | 63 (67) | 94 | 11 (69) | 16 | 52 (67) | 78 | ns | |
| 1 | 31 (33) | 94 | 5 (31) | 16 | 26 (33) | 78 | |||
| Histological Type | CDI | 88 (90) | 98 | 13 (81) | 16 | 75 (91) | 82 | ns | |
| CLI | 6 (6) | 98 | 3 (19) | 16 | 3 (4) | 82 | |||
| Other | 4 (4) | 98 | 0 (0) | 16 | 4 (5) | 82 | |||
| HG | 1 | 19 (20) | 94 | 4 (29) | 14 | 15 (19) | 80 | ns | |
| 2 | 37 (39) | 94 | 4 (29) | 14 | 33 (41) | 80 | |||
| 3 | 38 (40) | 94 | 6 (43) | 14 | 32 (40) | 80 | |||
| Tumor Stage | < III | 79 (82) | 96 | 14 (88) | 16 | 65 (81) | 80 | ns | |
| ≥ III | 17 (18) | 96 | 2 (12) | 16 | 15 (19) | 80 | |||
| Immunohistochemistry | ER | pos | 68 (70) | 97 | 11 (69) | 16 | 57 (70) | 81 | ns |
| PR | pos | 57 (59) | 97 | 6 (38) | 16 | 51 (63) | 81 | ns | |
| HER2 | pos | 20 (21) | 96 | 4 (25) | 16 | 16 (20) | 80 | ns | |
| Cadherin-E | pos | 84 (95) | 88 | 10 (77) | 13 | 74 (99) | 75 | 0.008 | |
| Ki-67 | high | 43 (47) | 92 | 5 (36) | 14 | 38 (49) | 78 | ns | |
| CK5/6 | pos | 18 (20) | 89 | 2 (18) | 14 | 16 (21) | 78 | ns | |
| EGFR | pos | 12 (14) | 85 | 0 (0) | 10 | 12 (16) | 75 | ns | |
| CK18 | pos | 80 (91) | 88 | 9 (75) | 12 | 71 (93) | 76 | ns | |
| P53 | pos | 43 (57) | 75 | 3 (30) | 12 | 40 (62) | 65 | ns | |
| PARP | pos | 67 (82) | 82 | 9 (82) | 11 | 58 (82) | 71 | ns | |
T: Tumor stage (T1 < 2 cm; T2 ≥ 2 cm); N: Node involvement (N0: Absence; N1: Presence); HG: Histological grade; CDI: Invasive ductal Carcinoma; CLI: Invasive lobular Carcinoma; ER: Estrogen receptor; PR: Progesterone receptor; HER2: Erythroblastic leukemia viral oncogene homolog 2 receptor; EGFR: Epidermal growth factor receptor; PARP: Poly-ADP-Ribose-Polymerase; pos: Positivity; %: percentage of positives; n: total number of cases; adjusted p: Holm’s adjusted χ2 p-value associated to the differences between the cluster groups; ns: not significant.